# The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study

> **NCT05300802** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cardiovascular Center Harapan Kita Hospital Indonesia** · enrollment: 15 (actual)

## Conditions studied

- Congenital Heart Disease in Children
- Cardiopulmonary Bypass

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dexmedetomidine Hcl 100 Mcg/mL Inj
- **DRUG:** Dexmedetomidine Hcl 100 Mcg/mL Inj

## Key facts

- **NCT ID:** NCT05300802
- **Lead sponsor:** National Cardiovascular Center Harapan Kita Hospital Indonesia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-16
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-07-16
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05300802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05300802, "The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05300802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*